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Surgeries to treat musculoskeletal wounds need to inhibit or prevent 
contaminating bacteria from causing an infection for optimal wound healing.  Current 
local drug delivery biomaterial systems, such as bone cement beads and chitosan paste, 
do not fully degrade and/or do not offer full wound coverage which may limit the 
efficacy of antibiotic therapy, respectively.  Chitosan paste is a biocompatible, degradable 
local drug delivery system which allows for complete wound coverage and decreases the 
diffusion distance of antibiotics to bacteria. This research used blended chitosan-
polyethylene glycol (PEG) pastes to improve biocompatibility, increased degradation 
rate, and provide efficient and effective elution of locally delivered antibiotics for 
musculoskeletal wounds.  PEG-blended chitosan pastes were tested against previously 
studied acidic chitosan paste and neutral 1% chitosan sponge.  The PEG-blended pastes 
also were fabricated to have lower acidity compared to past formulations to improve 
biocompatibility, maintain degradation properties, and to decrease the fabrication time.  
The blended chitosan/PEG pastes were shown to be biocompatible and released active 













The main body of this thesis in Chapter 3 is a journal article entitled “Blended 
Chitosan Paste for Infection Prevention: Preliminary Preclinical Evaluations.”  This 
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Statement of Clinical Problem 
A musculoskeletal wound occurs when bone and muscle tissue becomes damaged 
to the point where the tissues are vulnerable to the environment [25].  Lacerations, 
crushing forces, punctures, burns, and surgical incisions can all cause complex 
musculoskeletal wounds [5].  Civilians have an estimated 20% chance of infection from 
complex musculoskeletal wounds while soldiers have a 26.5% chance of infection, a 
number that increases to 65% if their wound involves an open fracture [17, 41, 16, 51].  
Complications arise when bacteria, such as Staphylococcus aureus (S. aureus) and 
Pseudomonas aeruginosa (P. aeruginosa), contaminate these wounds.  These pathogenic 
microorganisms form biofilms and cause decreased susceptibility and increased 
resistance to certain antibiotics through the exchange of genes [16, 13, 7] and this 
resistance can also be transferred between bacteria [2, 21].  Increasing the antibiotic 
levels to address increased resistance can cause harmful systemic side effects [20, 15].   
Many biomaterials, such as polylactic acid and polyglycolic acid, currently being 
used for local drug delivery devices, but many of these devices still leave behind non-
biocompatible byproducts that are from rapid degradation, partial degradation, or even no 
degradation [15, 40].  Additional surgeries or procedures are required to remove these 
devices when no degradation or incomplete degradation occurs or to address non-
biocompatible reactions to the device degradation products [40, 8].  Another common 
problem with these delivery devices is that they do not offer complete wound coverage.  





removal, broadens wound coverage, offers an expanded antibiotic selection, and causes 
less wound drainage would make for an ideal delivery system to prevent infection. 
Hypothesis and Research Objectives 
Chitosan paste blended with polyethylene glycol (PEG) will form a biocompatible 
and biodegradable local delivery system that is used for point-of-care loading of various 
antibiotics to prevent bacterial infections in musculoskeletal injuries.  Past research on 
chitosan paste required extensive modification of the ratio of acidic and neutral sponges 
to improve cell/tissue compatibility and lessen composite acidity.  The hypothesis is that 
lowering the acidity of the chitosan pastes will improve the compatibility while 
maintaining functionality of the previous composite pastes and eliminate the use of 
mixing neutral and acidic sponges while maintaining effective local antibiotic delivery 
function.  Research goals are: 
 To determine a paste combination made from chitosan and PEG that is 
injectable from a modified syringe while exhibiting improved 
cytocompatibilty compared to neutral 1% chitosan sponges  
 To find an enhanced formulation that offers complete wound coverage and is 
able to elute active antibiotics to prevent infections 
Through in vitro evaluations such as elution and cytocompatibility, the most effective 
combinations will be determined and evaluated in functional in vivo studies.  This 
hypothesis can be broken down into two major aims: 
 Aim 1: Refine range of paste variations using chitosan and PEG.  Test and screen 






 Aim 2: Test selected paste variations in proof of principle in vivo studies for 





























Musculoskeletal wounds occur when muscle and bone tissue becomes damaged, 
limiting their natural functions in movement and support, among others [25].  These 
injuries can be brought on by lacerations, crushing forces, punctures, burns, and surgical 
incisions [5].  An estimated ten percent of American civilians will experience a 
musculoskeletal wound and require hospitalization [5].  From Operation Enduring 
Freedom and Operation Iraqi Freedom alone, American soldiers have experienced over 
50,000 musculoskeletal injuries [33].  Musculoskeletal injuries are one of the most 
prevalent forms of injuries, accounting for more than three out of five accidental injuries 
per year and one of the leading causes of death in all age groups [5].  In both the civilian 
and military sectors, billions of dollars are spent treating and researching musculoskeletal 
wounds and injuries.  The average cost per patient hospitalized for a musculoskeletal 
wound was $25,000 in 2004 [17, 33].  
Wound Management 
Rapid treatment of musculoskeletal injury is a crucial element in reducing the 
risks of malunions, nonunions, infection, and amputation while also increasing the 
recovery time and quality of life for the patient [34].  Emergency first aid, fixation, 
irrigation, dressings, and closures are common methods used in the treatment of complex 
musculoskeletal wounds [34].  Systemic antibiotic therapy, debridement, and irrigation 
are administered in most musculoskeletal wounds first in the emergency room (ER) in 





musculoskeletal injury is fixed internally or externally and closed to keep out any 
additional contaminants [11].  Surgeons then evaluate the simple or complex fractures 
and decide between a rapid treatment or a definitive treatment to achieve the greatest 
bone repair.  Before the final wound dressing is applied, moist dressings may be packed 
into the wound, which will promote angiogenesis, before the wound has been closed [34].  
Along with these moist dressings, antibiotics can be used to help treat the wound.  
Antibiotics, that are typically delivered systemically through oral administration or 
intravenous injection, are used to fight infection but may be ineffective if the vasculature 
around the musculoskeletal injury is damaged [41, 20].  
Wound Complications 
When the vasculature surrounding the injury site becomes damaged, this 
vasculature loss often leads to decreased numbers of immune cells that are able to reach 
the wound, which in turn inhibits the ability of the immune system to inhibit infection 
and also decreases the amount of systemically administered antibiotic that can reach 
wounded tissue [41, 20].  Due to low antibiotic levels and limited number of immune 
cells, bacteria numbers can increase rapidly and can spread leading to infection in the 
musculoskeletal injury.  Complex civilian musculoskeletal wounds have an estimated 
20% chance of infection while injured soldiers have a 26.5% chance of their 
musculoskeletal wounds becoming infected and the incidence of infection increases to 
65% if soldiers experience an open fracture [13, 41, 16, 51].  Soldiers are often exposed 
to bombs, explosives, or gunshots which can result in open fractures that can be highly 





musculoskeletal wounds are difficult to treat and severely hinder healing often leading to 
additional surgeries, costs, and treatment time [3]. 
Wound Infection Complications 
To prevent bacterial infections in a musculoskeletal wound, the bacteria in the 
wound needs to be identified and eliminated.  Bacteria, such as Staphylococcus aureus (S. 
aureus) and Pseudomonas aeruginosa (P. aeruginosa), can form biofilms (when bacteria 
attach to a surface) which decreases their susceptibility to certain antibiotics [16, 13, 7] 
and this resistance can be transferred between bacteria [2, 21].  Also S. aureus and P. 
aeruginosa are common pathogenic microorganisms in many musculoskeletal wounds 
and infections [16].  As the use of antibiotics increases, bacteria have gained a tolerance 
to many commonly used antibiotic drugs [2, 21].  Bacterial resistance used to be 
primarily found in hospitalized patients because the bacteria that were found in the 
hospital gained tolerance against antibiotics being used to treat patients.  Now, antibiotic 
resistant bacteria can be found in community-acquired infections as well [2, 21].  
Bacterial interactions, adaptations, and metabolic activity, especially in a biofilm, have 
brought about the need for advanced therapies, including increased concentration of local 
antibiotics to treat these infections [15, 10].  High levels of systemic antibiotics can cause 
harmful side effects, such as nausea and hypersensitivity, to other organs and tissues in 
the human body [20, 15].  As an alternative to high systemic antibiotics, local antibiotic 
delivery system can be applied to increase the local antibiotic levels to inhibit the 
infection in the wound without subjecting the patient to elevated systemic antibiotic 







Current Local Drug Delivery Devices 
Though there are many types of biomaterials currently being used as local drug 
delivery devices, many of these biomaterials still leave behind potentially non-
biocompatible byproducts due to rapid degradation.  Degradable biomaterials such as 
polylactic acid (PLA) and polyglycolic acid (PGA) are used for local delivery, however, 
they can have non-biocompatible degradation byproducts [15].  These remaining 
degradation products may not be tissue compatible.  When incomplete degradation or no 
degradation occurs, additional surgery is required to remove the remaining pieces of the 
material [8].  Polymethylmethacrylate (PMMA) is a non-degradable bone cement that is 
commonly used to locally deliver antibiotics for musculoskeletal wounds [1].  When 
mixed with antibiotics, PMMA has been shown to reduce infections and acts as a 
structure to stabilize fractures or large bone defects [1].  However, PMMA has decreased 
material strength when it is loaded with antibiotics [1].  Due to PMMA not being 
biodegradable, an additional surgery is required to remove the PMMA for complete bone 
and wound healing to occur.  Another short-coming of the use of PMMA for local 
antibiotic delivery is that after the antibiotics have been depleted, bacteria could begin to 
adhere to the implant and become a site for infection [1].   
Hydrogels are also used for local drug delivery.  These hydrogels can be used to 
release antibiotics and have desirable properties such as being formable during surgery 
and being adhesive to wound tissue [22].  These hydrogels can be administered through a 
needle which increases their use flexibility but using these gels for larger wounds with a 





coverage.  Another commonly used drug delivery device is the bio-ceramic calcium 
sulfate, which acts as a local drug delivery system and a scaffold for bone repair [1, 48, 
47].  Calcium sulfate is completely biodegradable and promotes bone growth, but, much 
like PMMA, has disadvantages.  Having a high resorption rate, calcium sulfate can leave 
partial formation of regenerated tissue.  Also calcium sulfate can exhibit a fast release of 
antibiotics leading to decreased antibiotic levels in late elution time points to inhibit 
infections [40, 1, 18].  Because of the high resorption rate, the calcium sulfate can cause 
sterile drainage in the wound [40].  Having a local drug delivery system that does not 
require additional surgeries for removal, has enhanced wound coverage, expanded 
antibiotic selection, and less wound drainage is an ideal delivery system.  Developing a 
local drug delivery system made from chitosan could potentially solve some of these 
issues.  Chitosan has properties of tissue compatibility, complete degradation to 
biocompatible byproducts, and can be loaded with multiple antibiotics [12]. 
Chitosan 
Chitosan is a linear amino polysaccharide that is a product of the process of 
alkaline deacetylation of chitin from the exoskeletons of insects and crustaceans.  
Chitosan, which can be made from chitin, can be obtained inexpensively and in large 
quantities from the fishing industries that would otherwise be thrown out as waste [1].  
Chitosan and chitin have been studied and proven to have many biomedical uses 
including drug delivery, bone healing properties, and wound healing [1, 12].  Chitosan is 
a non-toxic material that has high biocompatibility [12].  Along with being 
biocompatible, chitosan is also biodegradable [12].   Chitosan is distinguished from chitin 





functional groups removed while chitin has less than 50%.  Studies have shown that 
chitosan used to treat musculoskeletal wounds degrade at different rates while chitosan 
degraded nominally [44, 28, 31].  Chitosan has been investigated for local drug delivery 
because of its biocompatibility properties and that its polymeric cationic characteristics as 
well as reactive functional groups that allow for many customizations and alterations to 
specialize the chitosan’s use [1, 12].  Being able to include different compounds and 
reactants within chitosan drug delivery system broadens the applications for the use of 
chitosan sponges to treat multiple ailments [36].  In humans, chitosan is degraded 
chemically through acid catalyzed degradation or through the use of enzymes by the 
process of depolymerization [12].  Enzymatic degradation is performed by lysozyme in 
the body, which has also been shown to degrade chitosan in vitro.  Lysozyme hydrolyzes 
chitosan’s glycosidic bonds into glucosamine and saccharide degradation byproducts [48, 
9].  These byproducts, which are polysaccharides, are compatible and are absorbed 
gradually back into the body [48, 9].   
Chitosan as a Local Drug Delivery Device 
Multiple types of chitosan devices have been designed for medical applications 
including membranes and scaffolds which assist in bone regeneration, beads that are 
preloaded with growth factors and antibiotics, films and coatings to apply on implants, 
pastes for use of delivery drugs, and sponges used for wound dressings [4, 43, 26, 38, 32, 
37].  Sponges can be made with different thicknesses and pore sizes to allow for different 
amounts of absorption capacity while also allowing the wound to exchange fluids with 
the sponge and protecting the wound from outside bacteria [37].  In the case of chitosan 





with greater surface area, allows for loading high concentrations of aqueous antibiotic 
solutions [38].  This increased porosity enhances the sponge’s ability to be used as a drug 
delivery device and as a scaffold to be used for wound and bone healing.  Chitosan 
sponges, when made, are acidic and require neutralization through the rinsing of 
deionized water in order for the pH levels to become neutral to help promote 
biocompatibility. 
Chitosan Sponges with Polyethylene Glycol 
Chitosan sponges were developed to be used as an adaptable drug delivery system 
that is biocompatible, degradable, and to be loaded with antibiotics [18, 43].  These 
sponges have been further modified at the University of Memphis with the addition of 
polyethylene glycol (PEG) which is a water soluble polymer that enables the sponge to be 
loaded with hydrophobic dispersants and antifungals [36, 37].  PEG has low toxicity and 
helps to increase the biocompatibility, elution, and degradability over the neutral chitosan 
sponges.   
Decreasing Diffusion Distance 
While chitosan sponges and PMMA beads are extremely useful for antibiotic 
delivery, they often are limited in their ability to conform to all the small crevices in a 
complex wound site which can allow the antibiotic to become diluted.  Chitosan paste 
may solve this clinical issue as shown in Figure A by being able to seep into the wound 
bed and combat the bacteria found in the wound.  Sponges loaded with PEG will be able 
to degrade at a quicker rate which allows the sponge to break down, release antibiotics, 







Figure A: Illustration of antibiotic diffusion distances between different biomaterials 
Chitosan Paste 
Chitosan paste was developed to have the properties of the neutral chitosan 
sponges, like biodegradability and biocompatibility, while also having the additional 
property of injectability.  The composite combines the solid elements of chitosan sponge 
with a paste-like gel carrier for a greater ability to deliver antibiotics to the infected area 
[19].  The chitosan paste also improves on chitosan’s adhesiveness which helps maintain 
the device within the wounded area allowing for higher drug diffusion between the 
device and the damaged tissue with contaminating microorganisms.  Being moldable, the 
paste is able to fit in tight crevices and offer full wound coverage.  From Figure A, more 
wound coverage and a decrease in diffusion distance, the paste is better equipped to 
penetrate deeper into infected areas and tissues which will enhance the effectiveness of 
the antibiotic therapy through a decreased diffusion distance.  The biopolymer chitosan 
paste can be altered to control elution and degradation rates for more consistent results.  
The paste is activated by a clinician on site with water-soluble antibiotics which enables 
the clinician to customize a device specific for the patient’s needs based on the doctor’s 





additional research is needed to further the functionality of the chitosan paste.  These past 
chitosan paste studies have shown that the degradation rates can be variable and could 
potentially produce a moderate inflammatory response in animal models from an 
injectable chitosan drug delivery system.  Smith et al. has also showed from these 
evaluations that the paste is easily adhesive, degradable and active in preventing bacterial 
infections but were too acidic [39, 42].  A continuation of the chitosan paste research was 
to use different formulations of acidic and neutral chitosan sponge to make chitosan 
paste.  Rhodes et al. tested different ratios (60:40, 40:60, and 50:50) and found that the 
50:50 acidic to neutral sponge offered improved biocompatibility, degradation, and 
elution. 
Current Work:  Chitosan Paste Blended with Polyethylene Glycol and Lowered 
Acidity 
For the paste device investigated in this body of work, two new paste 
formulations were created with the aim of lowering the acidity of the acidic sponge and 
alleviating the need for using a neutral/acidic sponge combination to fabricate chitosan 
paste.  In the making of the chitosan sponges, acetic acid is used to dissolve the chitosan 
into the solution.  While the acetic acid is used for dissolving chitosan, the acid also 
makes the sponges used for the paste too acidic for ideal cytocompatibility.  The first type 
of paste had the acetic acid was lowered from 1% to 0.85% and then was blended with 
1% of 8,000 g/mol PEG and 1% chitosan.  The second formulation also had the acetic 
acid lowered to 0.85% but was made with 0.5% of 8,000 g/mol PEG and 1% chitosan.  
Rhodes et al. 50:50 combination paste will be used as a control to compare results for 





cytocompatability, degradability, injectability, adhesivity, and antibiotic elution.  The 
pastes will be tested in vivo in a rat tibia model to assess the biocompatibility of the 
pastes with both hard and soft tissue.  The evaluation of the pastes will be assessed 
histologically to determine how the cells interact with each formulation.  The paste’s 
ability to prevent infection with biofilm bacteria will be evaluated in an infected mouse 
pin model.  A summary of past researchers and their improvements to the development of 
chitosan sponge and paste can be found in Table A. 
Table A: Summary of past research for chitosan sponge and paste. (Gamma and EtO refer 







BLENDED CHITOSAN PASTE FOR INFECTION PREVENTION: 




Local drug delivery devices offer an improved method for delivering antibiotics 
for musculoskeletal wounds.  However, current devices do not allow for complete wound 
coverage and do not address the need for reducing the antibiotic diffusion distance to help 
prevent contamination by bacteria or other microorganisms.  We blended 
chitosan/polyethylene glycol (PEG) pastes to increase biocompatibility, decrease 
fabrication time, and to lower the diffusion distance of the antibiotics.  Along with using 
a lowered acid concentration, the blended paste formulations were fabricated with 
differing amount of chitosan and PEG composites.  Are the blended pastes biocompatible 
and biodegradable?  Will they elute active antibiotics to inhibit bacteria in vitro?  And are 
they able to prevent infection in a preclinical model with hardware?  Our blended paste 
formulations were tested in vitro for elution, activity, cytocompatibility, degradability, 
and injectability along with in vivo models for biocompatibility and infection prevention.  
The blended pastes were shown to elute active antibiotics above the minimum inhibitory 
concentration in vitro and in vivo as well as having comparable biocompatibility than the 
neutral 1% chitosan sponges.  Our blended chitosan/PEG composite pastes exhibited 
quicker degradation rates than the chitosan sponge along with comparable 
cytocompatibility/biocompatibility and infection prevention.  Blended chitosan/PEG 
pastes can be used to deliver active antibiotics to musculoskeletal wounds to prevent 






Musculoskeletal wounds account for over 60% of accidental injuries in the United 
States [5].  A musculoskeletal injury can affect both civilians and military populations 
with around 10% of American civilians experiencing a musculoskeletal wound [5].  
Administering treatment to an injury quickly is crucial in decreasing risks of infection, 
malunions, nonunions, and amputation while improving the recovery time and quality of 
life for the patient [34].  When the vasculature surrounding the injury site becomes 
damaged, a decrease in immune cells that are able to reach the damaged tissue occurs 
which results in a decrease in the systemic antibiotic therapy’s effectiveness against 
contaminating bacteria in the wound [41, 20].  Complex civilian musculoskeletal wounds 
have an estimated 20% chance of infection while there is a 26.5% chance of a soldier’s 
wounds becoming infected and up to 65% if their wounds involve an open fracture [17, 
41, 16, 51].  Bacteria, such as Staphylococcus aureus (S. aureus) and Pseudomonas 
aeruginosa (P. aeruginosa), are common pathogens in musculoskeletal wounds and can 
form biofilms and gain resistance to certain antibiotic concentrations [16, 13, 7, 2].  This 
resistance can also be transferred between bacteria [21].  To address contaminated injury 
sites, a local antibiotic delivery system may be utilized to increase the antibiotic levels in 
the wound to prevent infection without risking patient side effects from high systemic 
antibiotic levels [20, 15].  
Many types of biomaterials, such as bone cement beads and calcium sulfate, are 
being used as local drug delivery devices.  These devices can leave behind non-
biocompatible degradation products due to rapid, partial, or no degradation and can cause 





could potentially have more compatible degradation byproducts, requires no additional 
surgeries, and decreases the diffusion distance would be helpful in treating 
musculoskeletal injuries. 
In previous studies, chitosan/PEG sponges were developed to be used as an 
adaptable drug delivery system that is biocompatible, degradable, and can be loaded with 
antibiotics.  But they were not able to offer full wound coverage for enhanced infection 
prevention and treatment [18, 43].  Our laboratory has fabricated a chitosan paste blended 
with PEG to improve the paste’s biocompatibility, biodegradability, antibiotic delivery 
properties, provide a greater wound coverage, and decrease diffusion distance as shown 
in Figure 1. 
 
Figure 1: Illustration of antibiotic diffusion distances between different biomaterials 
Chitosan is a linear amino polysaccharide that is a product of the process of 
alkaline deacetylation of chitin from the exoskeletons of crustaceans [1].  Chitosan is 
biocompatible, biodegradable, adhesive, and has reactive side groups [5, 1].  Chitosan 
sponges have been blended with PEG in previous research to aid in degradation and 





and helps to increase the biocompatibility and degradability over the initial neutral 
chitosan sponges [36].   
Our goal is to develop a biocompatible local drug delivery device that is able to 
elute active antibiotics in vivo.  To determine how effective these paste formulations are, 
we need to answer some questions. Are the blended pastes injectable from a modified 
syringe?  Will they adhere to the wound site and not migrate?  Are they biocompatible 
and biodegradable?  Will they elute active antibiotics to inhibit bacteria in vitro?  And are 
they able to prevent infection in a preclinical model with hardware? 
Materials and Methods 
Fabrication   
The chitosan/PEG paste was fabricated using Chitopharm S chitosan powder 
(Chitinor AS, Tromsø, Norway) with an 82.46 ± 1.679 degree of deacetylation and an 
average molecular weight of 250.6 kDA.  The 1%:1% paste {D} formulation was made 
by dissolving 1% w/v of 8,000 g/mol PEG into a 0.85% v/v of acetic acid in ultrapure 
water solution and then dissolving 1% w/v of chitosan.  The solution is then frozen 
overnight, lyophilized, and ground up.  The process to manufacture the 1%:0.5% paste 
{C} is the same with the exception of the amount of PEG being 0.5% w/v of 8,000 PEG.  
For the neutral portion of the paste {B}, 0.5% w/v of 6,000 g/mol PEG (Sigma Aldrich, 
St. Louis, MO) was dissolved in a 1% v/v acetic acid in deionized water solution and, 
following dissolution, 0.5% w/v of chitosan was dissolved in the same solution. The 
acidic portion of the paste {A} was made in the same manner, but dissolving only 1 % of 
chitosan alone in the acetic acid solution. Both solutions for the neutral and acidic 





overnight at -20 °C, and lyophilized in a benchtop freeze dryer (LabConco, Kansas City, 
MO) to create acidic, dehydrated sponges. To obtain the neutral sponges, they were 
immersed in 0.25 M sodium hydroxide (NaOH) and washed with deionized water until a 
neutral pH was reached, frozen at -20 °C overnight, and lyophilized again to create the 
neutral, dehydrated sponges.  Both the acidic and neutral sponges were ground separately 
into small flakes (≤ .3 cm) and then combined in a 1:1 weight ratio to be used to make the 
50:50 paste (Table 1).   
Table 1: Compositions of the sponges used to make the 50:50 (Type A & B), 1%:0.5% 




The flakes are hydrated with a phosphate buffered solution (PBS) in deionized water at 
7.5 times the dehydrated weight of solid flakes. All samples used for biological testing 
were sterilized with ethylene oxide gas (EtO) prior to hydration and allowed to degas for 
a minimum of 24-48 hours.  The steps used for preparation of the chitosan paste for 













Elution studies were conducted with a combination of vancomycin and amikacin 
antibiotics loaded in a 10 mg/mL concentration.  The pastes and neutral 1% control 
sponge were aliquoted into tubes at approximately 0.8 grams and were then hydrated with 
6 mL (7.5 x the dehydrated paste weight) of the antibiotic solution (n = 3).  They were 
then placed into a metal, hemispherical container with numerous holes (approximately 
1.5 mm in diameter) and the opening was wrapped with parafilm while covering none of 
the holes.  The containers were then placed into a 125 mL plastic Nalgene® container, 
para-film side down, and filled with 50 mL of PBS (Figure 3).  The lids were screwed on 
and the containers were placed inside an incubator at 37°C on a shaker (Stovall – The 
Belly Dancer, speed 2).  Samples for antibiotic activity were collected at 1, 3, 6, 12, 24, 






Figure 3: Preparation and setup for elution sampling 
Vancomycin concentrations were measured using a Thermo Scientific Dionex 
UltiMate 3000 Series HPLC and a BDS HYPERSIL reversed-phase C18 column (150 x 
4.6 mm).  The mobile phase for vancomycin was 30% acetonitrile and 70% potassium 
phosphate buffer.  Amikacin concentrations were measured by using an amino glycoside 
antibiotics detection method [23].   All eluate concentrations were normalized to standard 
curves with known concentrations of the antibiotic solution. 
Activity 
The activity of the vancomycin and amikacin eluted from the pastes and sponge 
were determined using zone of inhibition (ZOI) assays (n = 3).  Blank paper discs, 6 mm 
in diameter, were placed on trypticase soy broth (TSB) agar plates containing a lawn of S. 
aureus (ATCC 12598) or P. aeruginosa (ATCC 27317) and were hydrated with 20 μL of 
each eluate samples. The TSB agar plates were incubated at 37 °C and removed after 24 
hours and photographed.  ZOI diameters (mm) were measured. 
Enzymatic Degradation 
Enzymatic degradation has the similar initial setup as elution other than the paste 
was weighed to be approximately 0.666 grams, was hydrated with 5 mL of PBS, and that 
the samples were submerged in 50 mL of lysozyme solution (n = 6).  Samples were taken 





mg/mL in deionized water) was replaced every 24 hours.  Once removed from the 
incubator, the degraded samples were removed from the solution and transferred to an 
aluminum dish and placed in an oven at 80°C for 24 hours to dry.  The dried samples 
were then weighed and the percent chitosan/PEG paste remaining was calculated.  New 
samples were used at each time point due to the drying process being destructive to the 
paste.    
Cytocompatibility 
In vitro cytocompatibility was assessed by determining the cell viability of NIH 
3T3 cells after being in contact with the evaluated pastes and neutral 1% chitosan 
sponges which was a control. The pastes were weighed to be approximately 0.666 grams 
and were then hydrated with 5 mL of PBS.  Cells were seeded at 1 x 104 cells/mL and 
allowed to proliferate overnight on 24-well transparent tissue culture plates in media 
under standard cell culture conditions at 37 °C and 5% CO2 atmosphere. The media 
consisted of 0.8 mL High Glucose Dulbecco’s Modified Eagle Medium (DMEM) with 
10% fetal bovine serum (FBS) and 1% Normocin.  Approximately 0.3 mL of each paste 
was injected into a cell culture insert with a 3.0 μm pore size membrane, which were 
lowered into each well (n = 5/group).  Chitosan sponges were hydrated, placed in inserts, 
and lowered into wells for the control.  After 24 and 72 hours, the inserts containing the 
paste were removed and Promega Cell Titer-Glo Luminescent Cell Viability assay was 
used to determine cell viability by measuring luminescence at 590 nm and compared to a 








Injectability of the paste variations was compared by ejecting the paste from a 
standard 25 mL repeater pipette syringe with a modified 3.25 mm diameter tip opening 
with empty syringes used for control (n = 3).  The paste was weighed approximately to be 
0.8 grams and hydrated in a syringe with 6 mL of PBS.  Each syringe was fixed into an 
Instron Universal Testing Machine with a 5 kN load cell, automated by Instron’s Bluehill 
2 (v2.13) software, which compressed the syringe plunger at 1 mm/sec to fully eject the 
chitosan paste from the syringe and recorded the maximum ejection force for 
comparison. 
In Vivo Biocompatibility Assessment Rat Tibia Model (Proof of Principle) 
 
This study assessed the three paste variations with neutral 1% chitosan sponge as 
the control.  The pastes were weighed to be approximately 0.666 grams and both the 
pastes and sponge were hydrated with 5 mL of PBS.  The rats (Wistar rats, male) were 
anesthetized with isoflurane and anesthesia (UofM – IACUC 0758).  The right hind limb 
was shaved and scrubbed with betadine and isopropanol.  An approximate incision of 10 
mm was made with a #10 scalpel blade on the mediolateral surface of the leg and the 
muscle tissue was reflected to expose the proximal tibial surface which was roughened 
slightly and the bone site marked for identification.  The rats then received implanted 
paste or sponge respective to their group (n = 3/group).  Approximately 0.2 mL of paste 
was injected into each defect site.  Sutures were used to close tissue over the defect 
followed by a cyanoacrylate application.  The rats were placed on heating pads and 
monitored until they were awake and active.  For two days or longer, the rats received an 





swelling.  At sacrifice (after 7 days), the implant region, including the tibia and 
surrounding tissue, were excised and placed in 10% neutral formalin before undergoing 
histological processing with paraffin and/or plastic embedding.  Slices were taken 
perpendicular to the defect as illustrated in Figure 4. 
 
Figure 4: Illustration of slide preparation from histology 
These slices were then stained with hematoxylin and eosin (H & E) and the tissue 
response and amount of remaining paste will be determined and quantified by blinded 
reviewers.  The histology will be ranked on a scoring system of 0-5 (0 – no inflammation, 
5 – severe inflammation) [36]. 




 The paste types evaluated were 1%:1%, 1%:0.5%, 50:50 and the sponge control 
(neutral 1% chitosan sponge) all hydrated with an antibiotic solution, a combination of 
vancomycin and amikacin (10 mg/ml each), and then a 1%:0.5% paste group hydrated 
with PBS also used for a control (UAMS – IACUC 3579).  The pastes were weighed to 
be approximately 0.666 grams and both the pastes and the sponge were hydrated with 5 
mL of solution.  NIH-Swiss mice, 5-8 weeks old, were anesthetized with Isoflurane and 





pinch reflex and the reaction to light shined in the mice eyes.  The left leg was cleaned 
with povidine iodine and rinsed with 70% ethanol.  An incision was made at the knee and 
a femoral pin (sterile 0.25 mm insect pins) was surgically implanted as seen in Figure 5.   
 
Figure 5: Image showing location and placement of insect pin inside the mouse femur. 
The pin was then inoculated with 2 microliters of cultures of UAMS-1 strain of S. aureus, 
a clinical isolate obtained from an osteomyelitis patient [S. aureus (ATCC 12598)].  The 
paste was applied immediately after the implantation of the pin through injection of a 
volume around 0.05 mL or the neutral sponges were placed adjacent to the pin (n = 
3/group).  After suturing, the mice were returned to their cages, monitored daily.  
Animals were sacrificed 7 days after the treatment and the left femur was removed.  The 
soft tissue was then dissected from the bone and the femur was cut into small pieces, 
placed in a sterile saline and then homogenized.  The homogenates were diluted, plated 
on agar plates, and the viable microbial colonies were counted along with the colonies 
remaining on the pin. 
Results 
In Vitro Antibiotic Elution and Antibacterial Activity 
All paste formulations released steady concentrations above minimum inhibitory 





the 72 hour in vitro elution as compared to the sponge which released drugs in a typical 
burst fashion.  In Figures 6 and 7, the elution graph for amikacin and vancomycin can be 
found, respectively.  A two-way ANOVA test was used followed by a Tukey test to test 
for significant differences. 
 
 
Figure 6: Elution graph for amikacin (n = 3). (A significant difference is found whenever 
p < 0.05, * - significant difference between the 1%:1% and the 50:50 pastes, # - 
significant difference between the 1%:0.5% and 50:50 pastes, ᶲ - significant difference 
between the neutral 1% sponge and the 1%:1% paste, α – significant difference between 
the neutral 1% sponge and the 1%:0.5% paste, γ – significant difference between the 








Figure 7: Elution graph for vancomycin (n = 3). (A significant difference is found 
whenever p < 0.05, * - significant difference between the 1%:1% and 1%:0.5% pastes, # - 
significant difference between the neutral 1% sponge and the 1%:1%, 1%:0.5%, and 
50:50 pastes, ᶲ - significant difference between the neutral 1% sponge and the 50:50 
paste) 
 
Both vancomycin and amikacin were shown to be eluted and active through the 
72 hour time point.  Elution was measurably higher for vancomycin and amikacin in 
paste after 10 hours in comparison to the neutral sponge.  These results were tested by 
performing a zone of inhibition (ZOI) test and the results can be found in Table 2.  The 
ZOI tests also illustrated an increase in inhibition for paste against P. aeruginosa from 
hours 24 through 72.  Even though the elution graph for the neutral 1% sponge showed a 
higher elution rate of amikacin from 24 through 72 hours, the activity results from the 







Table 2: Zone of inhibition antibacterial activity results reported as the average ± 
standard deviation of the inhibited growth diameter using a solution combination of 
vancomycin and amikacin antibiotic eluates against (A) S. aureus and (B) amikacin 
antibiotic eluates against P. aeruginosa from 1%:1%, 1%:0.5%, and 50:50 chitosan paste 
formulations after 24 hours of direct contact (n = 3). (A significant difference is found 
whenever p < 0.05, # - significant difference between the 1%:0.5% and 50:50 pastes, ᶲ - 
significant difference between the 1%:1% and 1%:0.5% pastes, α – significant difference 
between the sponge and the 1%:1% paste, γ – significant difference between the sponge 
and the 1%:0.5% paste, β – significant difference between the sponge and the 50:50 
paste) 
 
S. aureus Zone of Inhibition Diameter (mm), n = 3 
Sample 
Groups 
Eluate Sampling Time Points (hours) 








14.66 ±  
0.57 
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0.57# 











































        
  
P. aeruginosa Zone of Inhibition Diameter (mm), n = 3 
Sample 
Groups 
Eluate Sampling Time Points (hours) 
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0.0 












































The enzymatic degradation study used lysozyme to evaluate biologically based 







degraded very quickly compared to the 50:50 paste which degraded at a slower rate 
(Figure 8). 
 
Figure 8: Enzymatic degradation results for the 1%:1%, 1%:0.5%, and 50:50 pastes 
undergoing enzymatic lysozyme degradation (n = 6). (A significant difference is found 
whenever p < 0.05, * - significant difference between the 50:50 paste and both the 
1%:1% and 1%:0.5% pastes, # - significant difference between the 1%:1% and 1%:0.5% 
pastes, ᶲ - significant difference between the 50:50 paste and the 1%:0.5% paste, α – 
historical control from Parker et al. [36], chitosan/PEG sponges from studies by Parker et 
al. degraded to between 20% and 40% remaining [36]) 
 
Cytocompatibility 
The results of the cytocompatibility testing are shown in Figure 9.  After exposing 
cells to the pastes and sponges for 1 and 3 days in culture, the 1%:1% and 50:50 paste 
formulations showed a 40-60% higher percent cell viability than the control neutral 1% 
sponges and was found to be significantly different on day 1.  The 1%:0.5% paste did 








Figure 9: In vitro direct contact cytocompatibility normalized to neutral 1% chitosan 
sponge (CS) control reported as the average ± standard deviation of percent cell viability 
(n = 5). (A significant difference is found whenever p < 0.05, * - significant difference 
between the paste and the control sponge, # - significant difference between the 50:50 
and 1%:0.5% pastes) 
 
Injectability 
For the injectability comparison test, all pastes were ejected with the 50:50 paste 
being used as a control (Figure 10) and then compared to the maximum ejection force 
that an individual could achieve of 330 N [3].  The 1%:1% and 1%:0.5% pastes required 






Figure 10: Injection force results from a modified syringe for the 1%:1%, 1%:0.5%, and 
50:50 paste formulations compared against air (n = 3). (A significant difference is found 
whenever p < 0.05, * - significant difference when compared to the 50:50 paste) 
 
In Vivo Biocompatibility Assessment Rat Tibia Model (Proof of Principle) 
 The three formulations of paste along with the neutral 1% sponge were tested for 
soft and hard tissue biocompatibility in a rat tibial model.  Similar to the 
cytocompatibility study, the 1%:1% paste had the greatest biocompatibility when 
compared to the 1%:0.5% and the 50:50 pastes with the 1%:0.5% paste having the 







Figure 11: Rat tibia model results with the neutral 1% sponge as the control (n = 3). 
Ranking score: 0 (no inflammation) – 5 (severe inflammation).  (Using an ANOVA on 
Ranks test, there was found to be no significant differences between the three paste 
formulations and the control sponge) 
 
There was no significant difference in inflammation scores found between the chitosan 
control sponge and the chitosan paste formulations.  Samples of the histology slides that 



























Figure 12: Histology slide examples (160X magnification). (A: 1%:1% paste, B: 
1%:0.5% paste, C: 50:50 paste, D: neutral 1% sponge) 
Functional Animal Model: Infection Prevention in a Mouse Pin Model (Proof of 
 
Principle) 
 In the infected pin model, the paste formulations and the control sponges hydrated 
with the antibiotic solution (vancomycin and amikacin both loaded at 10 mg/mL) 
prevented infection and growth of the S. aureus (ATCC 12598).  The 1%:0.5% paste 
hydrated with PBS was not able to prevent infection from S. aureus.  The amount of 






Figure 13: Remaining microbial colonies from the pin and femur (n = 3). (Using 
ANOVA on Ranks and Dunnet Post Hoc test a significant difference is found whenever p 
< 0.05, * - significant difference when compared to the pastes and sponges hydrated with 
the antibiotic solution) 
 
There was a significant difference between the pastes and sponges hydrated with the 
antibiotic solution versus the paste hydrated with PBS in the surrounding bone tissue.  
From the results, the 1%:1% and 1%:0.5% pastes were shown to be able to elute active 
antibiotics to combat contaminating bacteria from causing an infection. 
Discussion 
Infections in complex musculoskeletal wounds can lead to additional surgeries, 
longer treatment and recovery time, costs, and death [16, 13, 7, 3].  In musculoskeletal 
wounds where tissue damage and vasculature are compromised, systemic antibiotic 
delivery at therapeutic levels can be decreased while locally released antibiotics would be 





time reaching the bacteria found in the wound in therapeutic dosages [41, 20].  A device 
that is biocompatible, degradable, and can locally release active antibiotics would 
improve patient treatment outcomes and require fewer surgeries, and lower the risk of 
death [44, 32, 37].  Chitosan sponges and chitosan pastes have been investigated for use 
as local antibiotic delivery systems to address problems of infection and traumatic 
musculoskeletal injuries [44].  While chitosan delivery devices offer biocompatibility, 
degradability, and active antibiotic characteristics, chitosan pastes formulations offera 
improved wound coverage allowing for a decreased diffusion distance for the antibiotics 
to travel before reaching contaminating bacteria in the wound.  Our research questioned 
whether different formulations of chitosan paste would offer increased biocompatibility 
while maintaining degradability and active antibiotic release over 3 days in order to 
develop an improved local drug delivery device to address clinical needs for infection 
prevention. 
 Limitations in this preliminary study include small proof of principle evaluations 
in both in vivo biocompatibility and functional infection prevention assessment models.  
By increasing the in vivo sample size in both models, an enhanced understanding of the 
biocompatibility and infection prevention qualities would be obtained.  Using a 
musculoskeletal wound in a larger animal in the in vivo functional infection study would 
also better represent a bone/soft tissue defect that would reflect a complex 
musculoskeletal wound and potential infection variables that are found in a clinical 
setting.  Our main study objective was to improve biocompatibility, the neutral 1% 
chitosan sponge was selected for the control based on past biocompatibility results.  A 





formulations as the paste to evaluate the difference between the sponge versus the paste.  
With the discussed limitations, the PEG blended paste formulations have shown the 
potential to be used as local drug delivery devices to treat musculoskeletal wounds and 
infections.  These blended chitosan-PEG pastes have the ability for improving wound 
coverage and reducing antibiotic diffusion distance to the contaminating bacteria in the 
wound. 
 While other chitosan/PEG hydrogels have been shown to release cyclosporine A 
and bovine serum albumin in a steady release, these hydrogels were not tested for the 
activity or release of bovine serum albumin in vitro [6, 49, 24].  Neutral chitosan and 
chitosan/PEG combination sponges have been shown to release an initial burst release of 
vancomycin at 7% and 16% respectively but decreased significantly at longer time points 
[35].  Chitosan sponges made from acetic and lactic acid loaded with vancomycin 
reported that after 1 hour an initial burst of antibiotics was recorded but also experienced 
a significant decrease in antibiotics eluted thereafter [32].  Noel et al. found that the 
levels of vancomycin and amikacin eluates released from chitosan sponges remained 
active through hour 72 and hour 48, respectively.  The chitosan/PEG pastes that were 
evaluated in this study showed half the amount of initial antibiotic burst release but did 
display active antibiotic release through the 72nd hour for both vancomycin and amikacin 
in a dual loaded antibiotic approach.  Based on the in vivo infected pin model data, we 
believe that our pastes will be able to actively release antibiotics and may prevent 
infection. 
 A few published studies regarding the degradation properties of chitosan/PEG 





chloride or lauric aldehyde to help in localized therapeutic applications.  Developed by 
De Souza et al., the injectable blended hydrogel was tested for degradation in vivo in an 
intraperitoneally injected mouse model [14].  The results showed that 7.5% of the 
injectable hydrogel was remaining after 4 weeks.  Parker et al. used blended 
chitosan/PEG sponges (6,000 g/mol PEG) in a degradation comparison study to a neutral 
chitosan sponge.  After 6 days of lysozyme enzymatic degradation, approximately 60% 
of the sponge was remaining.  A lower degradation of 0-8% paste remaining was 
determined in the studied blended chitosan/PEG pastes.  Based on the rapid degradation 
of our chitosan/PEG paste formulations found in vitro and in vivo, we can predict that our 
paste has the potential to degrade in vivo over several days to weeks.   
The literature from past studies for chitosan/PEG hydrogels have reported 
acceptable biocompatibility [49, 24, 50].  These results also are comparable to the results 
found from testing performed on chitosan/PEG sponges and various chitosan hydrogels 
[35, 14, 46].  Results found from in vivo studies include immediate inflammation, tissue 
encapsulation from an implanted hydrogel, moderate inflammation from chitosan/PEG 
devices, and no inflammatory response from various hydrogels [24, 14, 50, 45, 27].  The 
evaluated blended chitosan/PEG paste formulations in our study received similar cellular 
response to that of the neutral 1% chitosan sponge in vitro which is comparable to the 
studies mentioned.  From the in vivo biocompatibility study, our pastes elicited a minimal 
to moderate inflammatory response.  From our results and past studies evaluating 
chitosan/PEG devices, our paste formulations would elicit a minimal inflammatory 





 In the literature, there are few studies that look into the injectability of a 
chitosan/PEG device.  Sprayable thermosensitive chitosan/PEG hydrogels were 
developed by Wu et al. for nasal drug delivery but they did not explicitly test 
injectability.  The device in the Wu study were hydrogels being injected from a needle 
while our paste was injected from a larger cannula device [50].  These researcher’s 
studies do not directly reflect our procedures because currently there is not a standardized 
injectability test.  
The chitosan/PEG pastes being investigated exhibit more rapid degradation and 
similar biocompatibility to other chitosan/PEG devices as well as showing an extended 
elution profile of active antibiotics.  When tested in vivo in an infected mouse model, the 
pastes were proven to be effective in preventing infections and bacterial growth.  
Chitosan sponge, while biocompatible and able to elute active antibiotics, is unable to 
offer complete wound coverage and leaves a distance for the antibiotics to travel before 
reaching the contaminating bacteria.  However, chitosan paste is able to migrate into the 
wound bed and release antibiotics closer to the bacteria.  In conclusion, the 1%:0.5% 
blended chitosan/PEG paste offers more ideal characteristics for being used as a local 
drug delivery device to deliver active antibiotics to musculoskeletal wounds to prevent 
infection and to provide a greater wound coverage. 
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This discussion will briefly discuss the data and conclusions from chapter 3 along 
with the results from the accelerated degradation and adhesion studies.  Detailed 
descriptions, results, and discussions from these additional studies can be found 
respectively in Appendices C and D.   
Infections in complex musculoskeletal wounds can lead to additional surgeries, 
longer treatment and recovery time, costs, and death [16, 13, 7, 3].  In musculoskeletal 
wounds where tissue damage and vasculature are compromised, systemic antibiotic 
delivery at therapeutic levels can be decreased while locally released antibiotics would be 
more effective in these wounds.  With reduced blood flow to the wound, antibiotics can 
have difficulty reaching the bacteria found in the wound in therapeutic dosages [41, 20].  
Local drug delivery devices assist in this clinical need by being able to be directly applied 
to the wound to release antibiotics locally to prevent infections.  A device that is 
biocompatible, degradable, and can locally release active antibiotics would improve 
patient treatment outcomes and require fewer surgeries, decrease additional cost, and 
lower the risk of death [44, 32, 37].  Chitosan sponges and chitosan pastes were 
developed to have greater biocompatibility and degradability [44].  While both chitosan 
sponge and paste local delivery devices offer biocompatibility, degradability, and active 
antibiotic characteristics, the chitosan paste offers a greater wound coverage allowing for 
a decreased diffusion distance for the antibiotics to travel before reaching contaminating 
bacteria in the wound.  Our research questioned whether if lowering the acetic acid 





maintaining degradability and active antibiotic release in order to develop an improved 
local drug delivery device to address clinical needs for infection prevention. 
 Limitations in this preliminary study include a small proof of principle 
evaluations in both in vivo biocompatibility and functional infection prevention 
assessment models.  By increasing the in vivo sample size in both models, an enhanced 
understanding of the blended pastes’ biocompatibility and infection prevention qualities 
would be obtained.  Using a larger musculoskeletal wound in a larger animal in the in 
vivo functional infection study and would also better represent a bone/soft tissue defect 
that would reflect a complex musculoskeletal wound and potential infection variables that 
are found in a clinical setting.  Since our main study objective was to improve 
biocompatibility, the neutral 1% chitosan sponge was selected for the control based on 
past biocompatibility results.  A more representative control for future studies would be 
to use sponges made of the same formulations as the paste to evaluate the difference 
between the sponge versus the paste.  With the discussed limitations to these preliminary 
studies, the PEG blended paste formulations have shown the potential to be used as local 
drug delivery devices to treat musculoskeletal wounds and infections.  These blended 
chitosan-PEG pastes have the ability for improving wound coverage and decreasing 
antibiotic diffusion distance to the contaminating bacteria in the wound. 
 While other chitosan/PEG hydrogels have been shown to release cyclosporine A 
and bovine serum albumin in a steady release, these hydrogels were not tested for the 
activity or release of bovine serum albumin in vitro [6, 49, 24].  Neutral chitosan and 
chitosan/PEG combination sponges have been shown to release an initial burst release of 





[35].  Chitosan sponges made from acetic and lactic acid loaded with vancomycin 
reported that after 1 hour an initial burst of antibiotics was recorded but also experienced 
a significant decrease in antibiotics eluted thereafter [32].  Noel et al. found that the 
levels of vancomycin and amikacin eluates released from chitosan sponges remained 
active through hour 72 and hour 48, respectively.  The chitosan/PEG pastes that were 
evaluated in this study showed half the amount of initial antibiotic burst release but did 
display active antibiotic release through the 72nd hour for both vancomycin and amikacin 
in a dual loaded antibiotic approach above the minimum inhibitory concentration (MIC).  
Based on the in vivo infected pin model data, we believe that our pastes will be able to 
actively release antibiotics and may prevent infection. 
 A few published studies regarding the degradation properties of chitosan/PEG 
products and hydrogels involved an injectable, chitosan phospholipid blended with lauric 
chloride or lauric aldehyde to help in localized therapeutic applications.  Developed by 
De Souza et al., the injectable blended hydrogel was tested for degradation in vivo in an 
intraperitoneally injected mouse model [14].  The results showed that 7.5% of the 
injectable hydrogel was remaining after 4 weeks.  Parker et al. used blended 
chitosan/PEG sponges (6,000 g/mol PEG) in a degradation comparison study to a neutral 
chitosan sponge.  After 6 days of lysozyme enzymatic degradation, approximately 60% 
of the sponge was remaining.  A lower degradation of 0-8% paste remaining was 
determined in the studied blended chitosan/PEG pastes.  Based on the rapid degradation 
of our chitosan/PEG paste formulations found in vitro and in vivo, we can predict that our 





 The literature concerning in vitro biocompatibility of chitosan/PEG hydrogels 
have been reported that the hydrogels do not cause cytotoxicity and are biocompatible 
[49, 24, 50].  These results also are comparable to the results found from testing 
performed on chitosan/PEG sponges and various chitosan hydrogels [35, 14, 46].  Results 
found from in vivo studies offer more variance from immediate inflammation and tissue 
encapsulation from an implanted hydrogel, to moderate inflammation from chitosan/PEG 
devices, to no inflammatory response from various hydrogels [24, 14, 50, 45, 27].  The 
evaluated blended chitosan/PEG paste formulations developed received similar cellular 
response to that of the neutral 1% chitosan sponge in vitro which is comparable to the in 
vitro studies mentioned.  From the in vivo biocompatibility study, our pastes elicited a 
minimal to moderate inflammatory response.  Based on our results and past studies 
evaluating chitosan/PEG devices, our paste formulations would elicit a minimal 
inflammatory response when used in a larger animal model. 
 In the literature, there are few studies that look into the injectability of a 
chitosan/PEG device.  Sprayable thermosensitive chitosan/PEG hydrogels were 
developed by Wu et al. for nasal drug delivery but they didn’t explicitly test injectability.  
Although, the device in the Wu study were hydrogels being injected from a needle while 
our paste was injected from a larger cannula device [50].  These researcher’s studies do 
not directly reflect our procedures because currently there is not a standardized 
injectability test. 
Additional blended paste evaluations which were not included in Chapter 3, 





The test used to achieve the accelerated degradation results was used from Martin 
et al. and used a cobalt dichloride solution to degrade the chitosan [29].  This study is 
more commonly used for polyurethane devices while we adapted methods for a 
degradation study to develop a rapid ranking assessment before conducting the enzymatic 
degradation.  The lysozyme based enzymatic degradation of the pastes would 
theoretically degrade in a similar mechanism as in a musculoskeletal wound.  The 
rankings of paste degradation were found to be consistent with the enzymatic degradation 
study showing that the 1%:1% paste degraded the quickest and the 1%:0.5% and 50:50 
pastes remained through longer time points. 
 To test the adhesivity of chitosan/PEG devices, we have not found an effective 
and accepted standard test to evaluate this characteristic.  Changes were made from 
Rhodes et al. adhesivity testing where we directly measured the migration of the 
chitosan/PEG devices so that each type could be compared against a neutral 1% chitosan 
sponge control [39].  The 50:50 combination paste results were consistent with the results 
from the Rhodes study while both the 1%:1% and 1%:0.5% pastes migrated  on average 1 
inch and 0.6 inches respectively. 
The chitosan/PEG pastes being investigated exhibit quicker degradation and 
similar biocompatibility to other chitosan/PEG drug delivery devices as well as showing 
a desirable elution profile of active antibiotics.  A comparison between each paste 








Table B: Comparison between paste formulations and neutral sponge. (‘ ’ - improved 
results, ‘–’- acceptable results, ‘X’ – less than desirable results) 
 
 
When tested in vivo in an infected mouse model, the pastes were proven to be 
effective in preventing infections and bacterial growth.  Chitosan sponge, while being 
biocompatible and able to elute active antibiotics, is unable to offer complete wound 
coverage and leaves a distance for the antibiotics to travel before reaching the 
contaminating bacteria.  However, chitosan paste is able to migrate into the wound bed, 
provide a greater wound coverage, and release antibiotics closer to the bacteria.  In 
conclusion, the 1%:1% and 1%:0.5% blended chitosan/PEG pastes can be used as a local 
drug delivery device to deliver active antibiotics to musculoskeletal wounds to prevent 

















 Based on the blended chitosan/PEG pastes evaluated in the studies presented in 
this paper, both blended pastes offer different advantages when used as a local drug 
delivery device.  While starting off with more acidic chitosan sponges made by Rhodes et 
al. and Smith et al., the 1%:1% and 1%:0.5% pastes offered similar biocompatibility 
results as the less acidic 50:50 combination paste from Rhodes’ studies.[39, 42]  The 
main goal of this project was to improve biocompatibility compared to the 50:50 chitosan 
paste.  Though our goal was not achieved, we were able to achieve comparable 
biocompatibility by decreasing the acidity of the paste to make a less acidic sponge and 
using 8,000 g/mol PEG in place of the 6,000 g/mol PEG.  Also by decreasing the acidity 
of the pastes and eliminating the need for combining acidic and neutral sponges, the 
fabrication process was shortened and requires only one lyophilization to manufacture the 
final product.  Because of the composition of the 1%:1% and 1%:0.5% pastes, the 
blended chitosan/PEG pastes degrade in half the time as the 50:50 paste which has an 
extended enzymatic degradation time frame.  Also from the composition of the pastes, 
the 1%:1% and 1%:0.5% pastes offer an injectability force of under 50 N compared to the 
approximately 150 N force needed for the 50:50 paste.  While there is a difference in 
composition, all three pastes are able to elute active antibiotics throughout the 72 hours of 
the study with the 50:50 paste eluting the most followed by the 1%:0.5% paste.   
Based on the results from the studies as well as the in vivo models, the 1%:0.5% 
paste has more suitable characteristics for a local drug delivery device from the 





better biocompatibility and the 1%:1% paste exhibits quick enzymatic degradation, the 
1%:0.5% paste has similar biocompatibility to past acidic pastes, a decreased fabrication 
time, and offers improved injectability from the 50:50 paste as well as better adhesive 








Even though the 1%:1% and 1%:0.5% chitosan/PEG pastes have been shown to 
have improved biocompatibility and active eluted antibiotics, additional expanded in vivo 
studies are needed.  Animal models with a larger sample size will help further solidify 
and confirm the biocompatibility, elution, and functional properties of the chitosan/PEG 
pastes. 
 Another aspect that needs to be evaluated is the type of sponge used for the 
control throughout the in vivo and in vitro studies.  The main goal of this research was to 
improve the biocompatibility of the chitosan pastes so the neutral 1% chitosan sponge 
was selected for the control due to its known biocompatibility.  While the neutral sponge 
is a great control for biocompatibility studies, a better control is needed for comparison of 
each type of paste.  Using a sponge made to the same specifications of the 1%:1% and 
1%:0.5% pastes will allow us to evaluate how the formulations work in sponge versus 
paste form. 
 Other future work can include looking into different combinations of chitosan 
versus PEG to determine which formulations work best for elution, degradation, and 
biocompatibility.  Using chitosan with different degrees of deacetylation and molecular 
weight could be evaluated to see how those specifications change biocompatibility.  With 
both of the 1%:1% and 1%:0.5% pastes having quick degradations over the course of the 
enzymatic degradation study, a paste with a decreased concentration of PEG and a higher 
concentration of chitosan may be able to provide a slower degradation to allow the paste 





infections.  Different molecular weights of PEG should also be tested to determine which 
weight offers the greatest results for use in a local drug delivery device. 
 Finally, looking into what can be loaded into the chitosan pastes should be 
evaluated like antifungals and growth factors.  Antifungals should be loaded into the 
pastes and tested to see if the applications for chitosan pastes can be broadened to offer a 
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APPENDIX A:  DETAILED MATERIALS AND METHODS FOR CHAPTER 3 
Fabrication   
All materials were purchased from Fisher Scientific (Pittsburgh, PA) unless 
otherwise noted. The chitosan/PEG paste was fabricated using Chitopharm S chitosan 
powder (Chitinor AS, Tromsø, Norway) with an 82.46 ± 1.679 degree of deacetylation 
and an average molecular weight of 250.6 kDA and/or polyethylene glycol with a 
molecular weight of 6,000 g/mol (PEG; Sigma Aldrich, St. Louis, MO). For the neutral 
portion of the paste, 0.5% w/v of 6,000 g/mol PEG was dissolved in a 1% v/v acetic acid 
in ultrapure water solution and, following dissolution, 0.5% w/v of chitosan was 
dissolved in the same solution. The acidic portion of the paste was made in the same 
manner, but dissolving only 1% w/v of chitosan in the acetic acid solution. Both solutions 
for the neutral and acidic sponge were cast into 500 mL containers at a volume of 
approximately 333 mL, frozen overnight at -20 °C, and lyophilized in a benchtop freeze 
dryer (LabConco, Kansas City, MO) to create acidic, dehydrated sponges. To obtain the 
neutral sponges, they were neutralized in 0.25 M sodium hydroxide (NaOH) and washed 
with ultrapure water until a neutral pH was reached, frozen at -20 °C overnight, and 
lyophilized again to create the neutral, dehydrated sponges.  Both the acidic and neutral 
sponges were ground separately into small flakes (≤ .3 cm) and then combined in a 50:50 
combination to be used to make the 50:50 paste.  The 1%:1% paste formulation was 
made by dissolving 1% w/v of 8,000 g/mol PEG into a 0.85% v/v of acetic acid in 
ultrapure water solution and then dissolving 1% w/v of chitosan.  The solution is then 
frozen overnight and then lyophilized and ground up with a coffee grinder.  The process 





amount of PEG being 0.5% w/v of 8,000 PEG.  In order to turn the ground sponges into a 
paste, the flakes are hydrated with a phosphate buffered saline (PBS) in ultrapure water 
solution at 7.5 times the paste’s dehydrated weight. All samples used for biological 
testing were sterilized with ethylene oxide (EtO) gas prior to hydration. 
Elution 
For elution, one study was run and the samples were loaded with a combination of 
vancomycin and amikacin both at a 10 mg per mL concentration.  The 1%:1%, 1%:0.5% 
and 50:50 pastes were hydrated with 5 mL of vancomycin or amikacin and then placed 
into a metal, hemispherical container with numerous holes (approximately 1.5 mm in 
diameter).  Each metal container was then covered with para-film while making sure that 
none of the holes were covered.  The container was then placed into a 125 mL plastic 
Nalgene container, para-film side down, and subsequently filled with 50 mL of 1× PBS.  
The lids were screwed and the containers were then placed inside an incubator at 37°C on 
a shaker.  Samples remained in the incubator at 37 °C until each time point.  Samples to 
be used for HPLC and antibiotic activity were collected at 1, 3, 6, 12, 24, 48, and 72 
hours with the PBS solution completely replaced at every time point (Figure B) (n = 3).  
All paste samples used were EtO sterilized.   
Vancomycin concentrations were measured using a Thermo Scientific Dionex 
UltiMate 3000 Series HPLC and a BDS HYPERSIL reversed-phase C18 column (150 x 
4.6 mm).  The mobile phase for vancomycin was 30% acetonitrile and 70% potassium 
phosphate buffer (0.0124 M KPO4 and 0.0876 M K2PO4).  Vancomycin had a 2.637-
minute retention time using a 1.0 mL/min flow rate with a 209 nm UV detection.  





detection method [23].   A buffer solution is made with 11.5 mL of .2M acetic acid, 14 
mL of .2M phosphoric acid, 12.5 mL of .2M boric acid, and 975 mL of deionized water 
and then the pH level brought to 2.7 with sodium hydroxide.  Then a formaldehyde 
solution is made by mixing 4 grams of para formaldehyde in 100 mL of deionized water 
at 60 °C and then adding sodium hydroxide to dissolve the para formaldehyde until 
solution is clear.  Finally a reaction solution is made by adding 2 mL of the buffer 
solution, 1 mL of acetyl acetone, and 10 mL of formaldehyde solution together.  Add 1 
mL of this reaction solution and 1 mL of the elution sample together and place in an oven 
at 100 °C for 20 minutes.  After being cooled to room temperature, place 100 μL of 
solution into black opaque 96 well plates and read at 410/471 (excitation/emission).  The 
detection range for this method is 100 μg/mL to 0.0039 μg/mL.  All eluate concentrations 
for both vancomycin and amikacin were normalized to standard curves with known 
concentrations.   
 
 
Figure B: Steps on how elution samples were prepared and time points were taken 
 
Activity 
The antibiotic activity of the vancomycin and amikacin eluted in vitro from the 
1%:1%, 1%:0.5%, and 50:50 paste variations were determined using zone of inhibition 





placed on a lawn of S. aureus (ATCC 12598) or P. aeruginosa (ATCC 27317) and were 
hydrated with 20 μL of vancomycin or amikacin eluate samples, respectively (n = 3). The 
TSB agar plates were incubated at 37 °C and removed after 24 hours where pictures were 
taken and ZOI diameters, not including the discs, were measured. 
Accelerated Degradation 
Accelerated in vitro degradation was assessed by the weight reduction of the 
1%:1%, 1%:0.5%, and the 50:50 combination chitosan/PEG paste variations over time.  
Dehydrated weights of each EtO sterilized paste combination were recorded prior to 
hydration (n = 3).  After being hydrated, each 5 mL sample was placed into a metal, 
hemispherical container with numerous holes (approximately 1.5 mm in diameter).  Each 
metal container was then covered with para-film while making sure that none of the holes 
were covered.  Make up a 0.1M CoCl2 solution by adding 2700 mL of deionized water, 
300 mL of 30% hydrogen peroxide, and then 71.37 grams of CoCl2 [29].  The container 
was then placed into a 125 mL plastic Nalgene container, para-film side up, and 
subsequently filled with 70 mL of the 0.1M cobalt dichloride solution making sure that 
each hole was submerged.  The lids were screwed on loosely to allow for the release of 
gas from the reaction.  The containers were then placed inside an incubator at 37°C on a 
shaker.  Samples remained in the incubator until each time point.  Samples were taken at 
2, 3, 4, 5, and 18 hour time points.  Once removed from the incubator, the degraded 
samples were removed from the solution and transferred to an aluminum dish and placed 
in an oven at 80°C for 24 hours to dry.  The dried samples were then weighed, and the 
percent chitosan/PEG paste remaining was calculated by dividing the degraded weight by 





point due to the drying process being destructive to the paste.  See Appendix C for results 
and statistical data. 
Enzymatic Degradation 
Enzymatic degradation utilized the same setup as the accelerated degradation 
study, with the exception of the EtO sterilized paste combinations being submerged in 50 
mL of lysozyme solution instead of 70 mL of cobalt dichloride to simulate how chitosan 
degrades in the body (n = 3).  The lysozyme solution was 1 mg/mL chicken egg white 
lysozyme in ultrapure water.  A lysozyme solution was used because in the body 
lysozyme is a major component in the degradation of chitosan [48, 9].  Samples were 
taken at 1, 2, 3, 4, 5, and 6 day time points and the samples remained within the incubator 
until they were taken with the exception of when the lysozyme solution was being 
replaced which happened every 24 hours.  Once removed from the incubator, the 
degraded samples were transferred to an aluminum dish and placed in a vacuum oven at 
80 °C for 24 hours to dry. The dried samples were then weighed, and the percent 
chitosan/PEG paste remaining was calculated by dividing this dry, degraded weight by 
the initial, dehydrated weight and multiplying by 100. Because the drying process was 
destructive to the samples, new samples were used for each time point for all three paste 
variations.   
Cytocompatibility 
In vitro cytocompatibility was assessed by determining the cell viability of NIH 
3T3 cells after being in contact with the 1%:1%, 1%:0.5%, 50:50 combination 
chitosan/PEG pastes and neutral 1% sponges (used as a control).  All paste and sponge 





allowed to proliferate on 24-well transparent tissue culture plates in complete media. The 
media consisted of 0.8 mL High Glucose Dulbecco’s Modified Eagle Medium (DMEM) 
with 10% fetal bovine serum (FBS) and 1 x Normalin. All of this was done under 
standard cell culture conditions at 37 °C and 5% CO2 atmosphere. Approximately 0.3 mL 
of each paste ratio was injected into a cell culture insert with a 3.0 μm pore size 
membrane, each of which was subsequently lowered into the media of one well (n = 5). 
Neutral 1% chitosan sponges were placed in inserts and lowered into wells for the 
control.  After the plates were incubated for 24 and 72 hours, the inserts containing the 
paste were removed and the Promega Cell Titer-Glo Luminescent Cell Viability assay 
was used to determine cell viability by measuring luminescence at 590 nm and compared 
to a standard curve.  
Injection 
Injectability of the 1%:1%, 1%:0.5%, and 50:50 chitosan/PEG paste variations 
was assessed by ejecting the paste from a standard 25 mL repeater pipette syringe with a 
modified 3.25 mm diameter tip opening with empty syringes used for control (n = 3).  
Each syringe was loaded with 6 mL of paste and fixed into an Instron Universal Testing 
Machine with a 5 kN load cell, automated by Instron’s Bluehill 2 (v2.13) software, which 
compressed the syringe plunger at 1 mm/sec to fully eject the chitosan/PEG paste from 
the syringe (Figure C). Maximum ejection force was recorded and compared to a 
clinically relevant maximum ejection force that an individual could achieve of 330 N [3].  






Figure C: Injection study setup 
Adhesion 
To determine the adhesiveness of the paste formulations, porcine cervical 
vertebrae were used as representative hard and soft tissues (Kroger, Memphis, TN) and 
coated in fetal bovine serum (FBS) to simulate blood-like components. Adhesion was 
visually assessed by adhering 5 mL of paste to the FBS coated tissue and timing its 
adherence for a minimum of 1 minute (n = 3). Each sample was then doused with 10 mL 
of PBS as simulated wound fluid to observe if this would dislodge the paste sample.  
Also the slippage distance was recorded using a ruler once the paste was applied and 
before the PBS was added.  After the PBS was administered, the pastes were evaluated 
with the ruler again to record the distance the paste had moved.  All paste samples used 
were EtO sterilized.  See Appendix D for results and statistical data. 
In Vivo Biocompatibility Assessment Rat Tibia Model (Proof of Principle) 
 
This study was planned for four treatments.  The groups were 1%:1% chitosan 
paste, 1%:0.5% chitosan paste, 50:50 chitosan paste, and neutral 1% chitosan sponge 
(which was used as the control).  There was no antibiotics associated with this study as 





paste formulations and a sponge control.  This initial study was a proof of principle study 
and only used 25% of the animals planned in the study outline and protocol (12 rats, 3 for 
each treatment – IACUC 0758).  The rats (Wistar rats, male) were anesthetized with 
isoflurane and anesthesia.  The right hind limb was shaved and scrubbed with betadine 
and isopropanol prior to surgery and 0.05 cc of Rimadyl was used for pain management.  
An approximate incision of 10 mm was made using a #10 scalpel blade on the 
mediolateral surface of the leg and the muscle tissue was reflected to expose the proximal 
tibial surface.  In each rat, the surface of the bone was roughened slightly and the bone 
site marked for identification.  The rats received implanted paste or sponge respective to 
their group.  Approximately 0.2 mL of paste was injected into each defect site.  
Subcutaneous sutures were used to close the soft tissue over the defect and were followed 
by cutaneous sutures and cyanoacrylate application.  During recovery, the rats were 
placed on heating pads and monitored until they awoke and then were returned to their 
housing facilities.  For two days, longer if needed, the rats received an injection of 
Rimadyl for pain management and their surgical sites were checked daily for redness and 
swelling.  At sacrifice (after 7 days), the implant region, including the tibia and 
surrounding tissue, were excised and placed in 10% neutral formalin.  The samples were 
then shipped, soaked in formalin, to University of Alabama at Birmingham where they 
underwent histological processing with paraffin and/or plastic embedding and were sliced 






Figure D: Illustration of slide preparation from histology 
These slices were then stained with hematoxylin and eosin (H & E) and the tissue 
response, amount of inflammation, and amount of remaining paste was determined and 
quantified by blinded reviewers.  The histology was ranked on a scoring system of 0-5 (0 
– no inflammation, 5 – severe inflammation) [36]. 
Functional Animal Model: Infection Prevention in a Mouse Pin Model (Proof of 
Principle) 
 For this animal model, there were 5 groups with 3 mice in each group.  Each type 
of paste (1%:1%, 1%:0.5%, 50:50) and the sponge control (neutral 1% chitosan sponge) 
were tested with a antibiotic solution combination of vancomycin and amikacin (10 
mg/mL each) and then a 1%:0.5% paste group was tested with PBS (UAMS – IACUC 
3579).  NIH-Swiss mice, 5-8 weeks old, were anesthetized with Isoflurane plus Avertin 
(0.4-0.6 mg/gm) and the adequacy of the anesthesia was confirmed by the toe pinch 
reflex and the reaction to light shined in the mice eyes.  Only after being sure of 
significant, deep anesthesia did procedures continue.  The left leg of each mouse was 
cleaned with povidine iodine and rinsed with 70% ethanol.  An incision, approximately 5 
mm, was made at the knee and a femoral pin (sterile 0.25 mm insect pins) was then 





inoculated with 2 microliters of cultures of UAMS-1 strain of S. aureus, a clinical isolate 
obtained from an osteomyelitis patient [S. aureus (ATCC 12598)].  The paste, implanted 
through injection, was applied immediately after the implantation of the pin with a 
volume around 0.05-0.08 mL and with the neutral sponges being placed adjacent to the 
pin.  After the incisions had been sewn up, the mice were returned to their cages and 
separated into their specific groups.  The mice were monitored daily and any that 
appeared moribund were euthanized using CO2.  Animals were sacrificed 7 days after the 
treatment and the left femur was removed.  The soft tissue was dissected from the bone 
and the femur was cut into small pieces and placed in a sterile saline.  The femur 
segments were then homogenized and the homogenates were diluted, plated on agar 

















APPENDIX B:  ZONE OF INHIBITION PHOTOGRAPHS 
Amikacin/Vancomycin Activity Results 
                     50:50              1%:1%          1%:0.5%      1% Sponge 
 
Figure E: Zone of inhibition photographs for the antibiotic combination of vancomycin 
and amikacin loaded chitosan/PEG paste and neutral 1% chitosan sponges over 72 hours 





                     50:50              1%:1%            1%:0.5%         1% Sponge 
 
Figure F: Zone of inhibition photographs for the antibiotic combination of vancomycin 
and amikacin loaded chitosan/PEG paste and neutral 1% chitosan sponges over 72 hours 





APPENDIX C:  ACCELERATED DEGRADATION DATA 
Materials and Methods 
Accelerated degradation has the similar initial setup as elution other than the paste 
was weighed to be approximately 0.666 grams and were hydrated with 5 mL of PBS (7.5 
x the dehydrated paste weight). Make up a 0.1M CoCl2 solution by adding 2700 mL of 
deionized water, 300 mL of 30% hydrogen peroxide, and then 71.37 grams of CoCl2.  
Then the plastic containers filled with 70 mL of the 0.1M cobalt dichloride solution with 
the lids were loosely placed to allow for the reactions release of gas (n = 3).  Samples 
were taken at 2, 3, 4, 5, and 18 hour time points.  At the time points, the samples were 
removed from the solution, transferred to an aluminum dish, and placed in an oven at 
80°C for 24 hours.  The samples were then weighed, and the percent chitosan/PEG paste 
remaining was calculated in relation to the initial weight.   
Results 
 From the accelerated degradation study, the 1%:1% paste degraded prior to the 
first time point taken at hour 2.  Both the 50:50 and the 1%:0.5% pastes showed a more 
gradual decline in percent weight degradation but were both completely gone by 18 hours 







Figure G: Accelerated degradation results for the 1%:1%, 1%:0.5%, and 50:50 paste 
formulations (n = 3). (A significant difference is found whenever p < 0.05, * - significant 
difference between the 1%:1% paste and both the 1%:0.5% and 50:50 pastes) 
 
Discussion 
 The 1%:1% paste formulation rapidly degraded away leaving no part of the initial 
paste behind before the 2 hour time point due to its low viscosity.  On the other hand, the 
1%:0.5% and 50:50 pastes degraded in a more linear pattern and there was no significant 
difference found between them.  The 1%:0.5% and 50:50 paste were able to remain 
longer because the pastes themselves are more compact and tend to not disassociate as 
quickly as the 1%:1% paste.  If the situation calls for a quick degradation, the 1%:1% 
paste would be the ideal candidate.  Although if the paste is needed in the wound for a 
longer duration then the 1%:0.5% and the 50:50 paste formulations would make for the 










APPENDIX D:  ADHESION DATA 
Materials and Methods 
To determine the adhesiveness of the paste formulations, porcine cervical 
vertebrae were used as representative hard and soft tissues (Kroger, Memphis, TN) and 
coated in fetal bovine serum (FBS) to simulate blood-like components. Adhesion was 
visually assessed by adhering 5 mL of paste to the FBS coated tissue and timing its 
adherence for a minimum of 1 minute (n = 3). Each sample was then doused with 10 mL 
of PBS as simulated wound fluid to observe if this would dislodge the paste sample.  
Also the slippage distance was recorded using a ruler once the paste was applied and 
before the PBS was added.  After the PBS was administered, the pastes were evaluated 
with the ruler again to record the distance the paste had moved (Figure H).  All paste 
samples used were EtO sterilized. 
 
 
Figure H: Steps for obtaining adhesion results 
Results 
During the adhesion study, both the 50:50 and 1%:0.5% paste formulations 
exhibited minimal or hardly noticeable migration during the minute prior to being doused 
in PBS.  However, the 1%:1% paste immediately began to migrate down the tissue.  After 





began to migrate down.  The 1%:1% paste showed the most migration and potentially 
could have migrated further but the amount of tissue used was limited.  The 1%:0.5% 
paste migrated on average around 0.6 in. while the 50:50 paste remained adhered to its 
initial application point (Figure I).  The statistical analysis was done using a one-way 
ANOVA test followed by a Tukey test. 
 
Figure I: Adhesion results showing the migration distances between the 1%:1% paste, 
1%:0.5% paste, 50:50 paste and the neutral 1% chitosan sponge used for control (n = 3). 
(A significant difference is found whenever p < 0.05, * - significant difference between 
the signified paste/sponge type versus the 1%:1% paste formulation) 
 
Discussion 
 The adhesion test aims to evaluate how well the pastes adhere to tissue.  The 
50:50 paste when doused with PBS remained unmoved.  Being less viscous the 1%:0.5% 
migrated down the tissue shortly after the PBS was administered.  The 1%:1% paste is 
the least viscous of the three paste variations and began migrating soon after being 
































APPENDIX E:  PRELIMINARY CHITOSAN/PEG PASTE REFINEMENT DATA 
Objective 
 The goal of these experiments was to evaluate if through accelerated degradation 
and cytocompatibility studies the use of the 1%:1% and 1%:0.5% paste formulations 
were viable for further testing. 
Materials and Methods 
 Appendix A is where detailed steps for fabrication, accelerated degradation, and 
cytocompatibility can be found used to test these paste formulations. 
Fabrication 
The acidic 1% chitosan and neutral 1% chitosan/PEG products were ground 
separately into a powder, and combined into a 50:50 acidic to neutral ratio while the 
1%:1% and 1%:0.5% products where ground straight into a powder. A 1× phosphate 
buffered saline (PBS) in deionized water solution at 7.5 times the paste’s dehydrated 
weight was added to the dehydrated chitosan powder to form a hydrated chitosan/PEG 
paste (formulations can be seen in Table C).  For these preliminary studies none of the 
pastes were sterilized. 












In vitro cytocompatibility was assessed by determining the cell viability of normal 
human dermal fibroblast (NHDF) cells after being in contact with the 1%:1%, 1%:0.5%, 
and 0.5%:0.5% combination chitosan/PEG paste variations with future plans for 
replication. Cells were seeded at 1 x 104 cells/mL and allowed to proliferate on 12-well 
transparent tissue culture plates in complete media and approximately 0.5 mL of each 
paste ratio was injected into a cell culture insert. After the plates were incubated for 24 
and 72 hours, the inserts containing the paste were removed and the Promega Cell Titer-
Glo Luminescent Cell Viability assay was used to determine cell viability by measuring 
luminescence at 590 nm.  Luminescence values were normalized to untreated NHDF 
cells on tissue culture plastic (TCP) at each time point to determine percent cell viability.  
Plans are to replicate study to solidify results. 
Initial Accelerated Degradation 
Preliminary in vitro degradation was assessed by weight reduction of the 50:50, 
1%:1%, and 1%:0.5% paste formulations over time (n = 3). Samples were taken at 2, 3, 4, 
5, and 18 hour time points with plans for replication along with an enzymatic 
degradation.  The percent of paste remaining was calculated by dividing the dry, 
degraded weight by the initial, dehydrated weight and multiplying by 100.  New samples 
were used for each time point because the drying process is destructive to the paste.  A 
replicate experiment with lysozyme is needed to imitate what happens in vivo. 
Statistical Analysis 
Accelerated degradation and cytocompatibility testing were analyzed using two-





are presented as the average ± standard deviation and evidence of a statistically 




 Percent cell viability results for the 1%:1%, 1%:0.5%, and 50:50 are shown in the 
figure below. While all samples showed a significant increase in cell growth over time, 
the percent cell viability of each paste combination significantly decreased from 24 to 72 
hours. The 1%:1% paste combination showed the highest cell growth over time as well as 
the highest percent cell viability over the 24 and 72 hours (Figure J).  The data was 
analyzed by using a two-way ANOVA test and there was a statistically significant 
difference (P = 0.049) found.  A Holms-Sidak test was used to find between which 
groups that the difference occurred.  By switching to the less conservative Tukey test, the 
statistically significant difference was found to be between the untreated cells and the 









Figure J: In vitro direct contact biocompatibility normalized to tissue culture plastic 
(TCP) control reported as the average ± standard deviation of percent cell viability for 
1%:1%, 1%:0.5%, and 0.5%:0.5% combination chitosan/PEG paste (CPP) variations 
after 24 and 72 hours (n = 5). 
 
Initial Accelerated Degradation 
 Figure H, below, shows the percentage of the chitosan/PEG paste combinations 
remaining for all three variations between the 2, 3, 4, 5, and 18 hour time points.  The 
1%:1% paste was fully degraded even before the 2 hour time interval.  That specific paste 
is less viscous than the other paste combinations tested which allowed for its quick 
degradation.  The 1%:0.5% paste showed a steady increase in degradation throughout the 
study while the 50:50 paste increased slowly before becoming completely degraded 
(Figure K).  All of these paste combinations were not sterilized for this experiment and 
may behave differently after sterilization.  Using a two-way ANOVA test a statistically 
significant difference (P = 0.033) was found.  The Holms-Sidak test found that there was 
a statistically significant difference was between the 1%:0.5% and the 1%:1% paste 







Figure K: In vitro enzymatic accelerated degradation reported as the average ± standard 
deviation of weight percent remaining of the sample for 1%:1%, 1%:0.5%, and 50:50 
combination chitosan/PEG paste (CPP) variations over 18 hours (n = 3). The 50:50 paste 
was used as a control. 
 
Discussion 
The degradation results showed that each of the three paste combinations will 
degrade over time with the 1%:1% chitosan/PEG configuration degrading the best 
followed by the 50:50 and the 1%:0.5% respectively.  From the biocompatibility results, 
the 1%:1% paste exhibited the greatest cell viability.  The 1%:0.5% showed better 
percent cell viability than the 0.5%:0.5% paste after the first day but they were similar 
after the third day.  Based on these results, research should be continued using the 









APPENDIX F: PRELIMINARY ELUTION AND ZONE OF INHIBITION 
PHOTOGRAPHS 
Materials and Methods 
Elution studies were run with vancomycin and then with amikacin.  The pastes 
were hydrated with 6 mL of 5 mg/mL of vancomycin or amikacin in PBS and then placed 
into a metal, hemispherical container with numerous holes (approximately 1.5 mm in 
diameter), and covered with para-film while covering none of the holes.  The containers 
were placed into a 125 mL plastic Nalgene container, para-film side up, and filled with 
50 mL of 1× PBS.  The lids were screwed on and the containers were then placed inside 
an incubator at 37°C on a shaker.  Samples for antibiotic activity were collected at 1, 3, 6, 
12, 24, 48, and 72 hours with the PBS solution replaced at every time point.  
Vancomycin and amikacin concentrations were measured utilizing a BDS 
HYPERSIL reversed-phase C18 column (150 x 2.1 mm) from Thermo Scientific.  The 
mobile phase for vancomycin was 30% acetonitrile and 70% sodium phosphate buffer 
(0.0124 M NaPO4 and 0.0876 M Na2PO4) and the mobile phase for amikacin was 80% to 
10% of a buffer solution (.2 M acetic acid, .2 M phosphoric acid, .2 M boric acid with a 
pH of 2.7) and then with 20% to 90% of acetonitrile with the gradient happening over an 
eight-minute time frame.   
In Vitro Antibiotic Elution and Antibacterial Activity Results 
All paste formulations released steady concentrations of amikacin and 
vancomycin over the 72 hour in vitro elution.  Vancomycin had a 2.637-minute retention 
time using a 1.0 mL/min flow rate with a 209 nm UV detection.  Amikacin had a 1.532-
minute retention time using a 1.0 mL/min flow rate with a 450 nm fluorescence detection.  





of vancomycin and amikacin (Figures L and M).  A one-way ANOVA test was used 
followed by a Tukey test. 
 
 
Figure L: Elution graph for amikacin. (A significant difference is found whenever p < 
0.05, * - significant difference between the 1%:1% and 1%:0.5% pastes, # - significant 
differences between the 50:50 and 1%:1% pastes, ᶲ - significant difference between the 




Figure M: Elution graph for vancomycin. (A significant difference is found whenever p < 
0.05, * - significant difference between the 1%:1% and 1%:0.5% pastes, # - significant 
differences between the 50:50 and 1%:1% pastes, ᶲ - significant difference between the 






Loaded with vancomycin, the pastes remained active all the way through hour 72 
with the exception of the 1%:0.5% paste which was active through hour 48.  However, 
the pastes with amikacin remained active through hour 48 (Table D).   
Table D: Zone of inhibition antibacterial activity results reported as the average ± 
standard deviation of the inhibited growth diameter using (A) vancomycin antibiotic 
eluates against S. aureus and (B) amikacin antibiotic eluates against P. aeruginosa from 
1%:1%, 1%:0.5%, and 50:50 chitosan paste formulations after 24 hours of direct contact 
(n = 3). (A significant difference is found whenever p < 0.05, * - significant difference 
between the 1%:1% and 50:50 pastes, # - significant difference between the 1%:0.5% and 
50:50 pastes, ᶲ - significant difference between the 1%:1% and 1%:0.5% pastes) 
 
S. aureus Zone of Inhibition Diameter (mm), n = 3 
Sample 
Groups 
Vancomycin Eluate Sampling Time Points (hours) 






13.3 ±  
0.57 
11.3 ±  
0.57 













13.6 ±  
0.57 
12.0 ±  
1.0 








12.3 ±  
0.57 
12.0 ±  
0.0 




12.0 ±  
0.0*# 
        
  
P. aeruginosa Zone of Inhibition Diameter (mm), n = 3 
Sample 
Groups 
Amikacin Eluate Sampling Time Points (hours) 








 10.6 ±  
0.57 
11.0 ±  
1.0 








11.3 ±  
0.57 
12.3 ±  
0.57 
10.3 ±  
0.57# 






10.6 ±  
0.57* 
11.3 ±  
0.57 



















Amikacin Activity Results 




Figure N: Zone of inhibition photographs for amikacin loaded chitosan/PEG paste over 





Vancomycin Activity Results  
50:50             1%:1%           1%:0.5% 
 
 
Figure O: Zone of inhibition photographs for vancomycin loaded chitosan/PEG paste 













APPENDIX H: IACUC ANIMAL USE PROTOCOL APPROVAL LETTER - 
UAMS 
 
